Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pacritinib

- PMLiVE

Baxalta will add $2.5bn in new product turnover by 2020

Pro forma sales expected to grow up to 8% between 2016 and 2020

- PMLiVE

Baxter buoys cancer presence with $900m Oncaspar deal

Leukaemia drug will be added to upcoming biopharma firm Baxalta

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

- PMLiVE

Novartis biosimilar blocked by US court

Swiss firm’s Neupogen copy has its injunction upheld at appeal

- PMLiVE

EMA clears Novartis’ lung cancer drug Zykadia

First treatment option in Europe for patients with ALK-postitive NSCLC

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

- PMLiVE

Baxter and Merrimack file pancreatic cancer drug in EU

MM-398 is thought to help direct the active drug into tumours

- PMLiVE

Pfizer falls as strong dollar and generic erosion bites

First quarter results beat analysts’ estimates but sales still sliding

- PMLiVE

Novartis still hungry after absorbing GSK oncology

CEO says firm is looking to strengthen pipelines in its three businesses

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

Novartis knocks Pfizer off sales leader board

Swiss firm takes US giant’s crown as diversification programme and pipeline come to fruition

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links